Table 5

ORs with 95% CIs of developing endometrial cancer according to quartiles of levels of compound groups (nmol/g lipid)^a

Group of compounds	Model^b	OR (95% CI)						P for trend^c
Group of compounds	Model^b			Quartile 1	Quartile 2	Quartile 3	Quartile 4	P for trend^c
All PCBs^d	Age-adjusted	1.0	1.2 (0.6–2.3)	1.4 (0.7–2.6)	1.5 (0.8–2.8)	0.23
	Multivariate	1.0	1.1 (0.6–2.2)	1.1 (0.6–2.2)	1.2 (0.6–2.2)	0.72
Estrogenic compounds, not including CB 153^e	Age-adjusted	1.0	1.4 (0.7–2.7)	1.6 (0.8–3.2)	1.7 (0.8–3.4)	0.15
	Multivariate	1.0	1.2 (0.6–2.4)	1.2 (0.6–2.4)	1.2 (0.6–2.4)	0.76
Estrogenic compounds, including CB 153^f	Age-adjusted	1.0	1.3 (0.7–2.4)	1.0 (0.5–2.0)	1.2 (0.6–2.4)	0.74
	Multivariate	1.0	1.1 (0.6–2.1)	0.9 (0.4–1.7)	1.1 (0.6–2.2)	0.90
Antiestrogenic compounds^g	Age-adjusted	1.0	1.8 (0.9–3.4)	1.7 (0.9–3.4)	1.7 (0.8–3.3)	0.22
	Multivariate	1.0	1.7 (0.9–3.3)	1.4 (0.7–2.8)	1.5 (0.7–3.0)	0.48
Compounds with no known hormonal effect,	Age-adjusted	1.0	1.2 (0.6–2.3)	1.6 (0.9–3.0)	1.6 (0.9–3.1)	0.08
including p,p′-DDE^h	Multivariate	1.0	1.2 (0.6–2.2)	1.4 (0.7–2.7)	1.3 (0.7–2.4)	0.39
Compounds with no known hormonal effect,	Age-adjusted	1.0	1.8 (1.0–3.4)	1.4 (0.7–2.7)	1.3 (0.6–2.5)	0.83
excluding p,p′-DDEⁱ	Multivariate	1.0	1.9 (1.0–3.6)	1.6 (0.8–3.2)	1.5 (0.7–3.0)	0.47

^a Including women with levels below the quantification limit (half of the quantification limit was taken as an estimated value).
^b Multivariate adjusted for age and BMI.
^c Tests for trend were performed by assigning consecutive integers to levels of categorized variables.
^d CB 28, CB 52, CB 101, CB 105, CB 118, CB 138, CB 153, CB 156, CB 167, and CB 180.
^e o,p′-DDT; p,p′-DDT; p,p′-DDD;β -HCH; γ-HCH; trans-nonachlor; oxychlordane; CB 28; CB 52; and CB 101.
^f o,p′-DDT; p,p′-DDT; p,p′-DDD;β -HCH; γ-HCH; trans-nonachlor; oxychlordane; CB 28; CB 52; CB 101; and CB 153.
^g CB 105, CB 118, CB 156, and CB 167.
^h α-HCH, CB 138, CB 180, HCB, and p,p′-DDE.
ⁱ α-HCH, CB 138, CB 180, and HCB.